These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

989 related articles for article (PubMed ID: 32467592)

  • 1. Immune checkpoint signaling and cancer immunotherapy.
    He X; Xu C
    Cell Res; 2020 Aug; 30(8):660-669. PubMed ID: 32467592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy.
    Xu J; Brosseau JP; Shi H
    Oncogene; 2020 Nov; 39(48):7106-7113. PubMed ID: 33024277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-coding RNA and immune-checkpoint inhibitors: friends or foes?
    Shek D; Read SA; Akhuba L; Qiao L; Gao B; Nagrial A; Carlino MS; Ahlenstiel G
    Immunotherapy; 2020 May; 12(7):513-529. PubMed ID: 32378480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
    Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
    Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
    Kalantari Khandani N; Ghahremanloo A; Hashemy SI
    J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
    Rotte A; Jin JY; Lemaire V
    Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies.
    Zhou B; Gao Y; Zhang P; Chu Q
    Front Immunol; 2021; 12():693609. PubMed ID: 34194441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudoprogression and hyperprogression after checkpoint blockade.
    Wang Q; Gao J; Wu X
    Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of immune escape in the cancer immune cycle.
    Tang S; Ning Q; Yang L; Mo Z; Tang S
    Int Immunopharmacol; 2020 Sep; 86():106700. PubMed ID: 32590316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
    Yan Y; Zhang L; Zuo Y; Qian H; Liu C
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
    Ma W; Gilligan BM; Yuan J; Li T
    J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapies targeting the PD-1 signaling pathway.
    Iwai Y; Hamanishi J; Chamoto K; Honjo T
    J Biomed Sci; 2017 Apr; 24(1):26. PubMed ID: 28376884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymic expression of immune checkpoint molecules and their implication for response to immunotherapies.
    Caruso B; Moran AE
    Trends Cancer; 2023 Aug; 9(8):666-678. PubMed ID: 37173189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.